Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].
作者信息
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Caputo R, Cianniello D, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G
机构信息
Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Department of Public Health, University of Naples "Federico II", Naples, Italy.
出版信息
ESMO Open. 2021 Apr;6(2):100097. doi: 10.1016/j.esmoop.2021.100097.
Abstract
摘要
相似文献
1
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].《艾日布林联合贝伐单抗作为一线紫杉醇和贝伐单抗治疗后进展的HER2阴性转移性乳腺癌的二线治疗：一项多中心、II期、单臂试验（GIM11-BERGI）》勘误：[《ESMO Open》第6卷，第2期，2021年4月，100054]
ESMO Open. 2021 Apr;6(2):100097. doi: 10.1016/j.esmoop.2021.100097.
2
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).艾立布林联合贝伐珠单抗二线治疗 HER2 阴性转移性乳腺癌：紫杉醇联合贝伐珠单抗一线治疗进展后的多中心、II 期、单臂试验（GIM11-BERGI）。
ESMO Open. 2021 Apr;6(2):100054. doi: 10.1016/j.esmoop.2021.100054. Epub 2021 Feb 16.
3
A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.一项评价疗效、安全性和患者报告结局的Ⅱ期、多中心、单臂试验：以表柔比星或多西他赛为基础的化疗作为曲妥珠单抗后二线或三线治疗用于 HER2 阴性晚期或转移性乳腺癌。
Cancer Chemother Pharmacol. 2018 May;81(5):923-933. doi: 10.1007/s00280-018-3567-y. Epub 2018 Mar 28.
4
A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.一项关于艾日布林作为HER2阴性局部晚期或转移性乳腺癌一线化疗的II期多中心单臂试验。
Springerplus. 2016 Feb 24;5:164. doi: 10.1186/s40064-016-1833-1. eCollection 2016.
5
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.紫杉醇、贝伐单抗和依维莫司/安慰剂作为HER2阴性转移性乳腺癌患者的一线治疗：莎拉·坎农研究所的一项随机安慰剂对照II期试验。
Breast Cancer Res Treat. 2015 Nov;154(1):89-97. doi: 10.1007/s10549-015-3599-5. Epub 2015 Oct 12.
6
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.贝伐珠单抗联合紫杉醇对比贝伐珠单抗联合卡培他滨作为 HER2 阴性转移性乳腺癌一线治疗（TURANDOT）：一项随机、开放标签、非劣效性、III 期临床试验的主要终点结果。
Lancet Oncol. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1. Epub 2016 Aug 5.
7
Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.甲磺酸艾瑞布林二线或三线治疗局部晚期或转移性乳腺癌的 II 期临床试验：多中心、单臂试验。
BMC Cancer. 2018 Jun 28;18(1):701. doi: 10.1186/s12885-018-4628-7.
8
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.贝伐珠单抗联合化疗对比化疗作为一线治疗联合贝伐珠单抗化疗后 HER2 阴性局部复发或转移性乳腺癌患者的二线治疗（TANIA）：一项开放标签、随机 3 期试验。
Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28.
9
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.紫杉醇和贝伐珠单抗联合或不联合卡培他滨作为 HER2 阴性局部复发性或转移性乳腺癌的一线治疗：一项多中心、开放标签、随机 2 期试验。
Eur J Cancer. 2014 Dec;50(18):3077-88. doi: 10.1016/j.ejca.2014.10.008.
10
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.曲贝替定（AMG 386）联合每周一次紫杉醇，联合或不联合贝伐单抗作为HER2阴性局部复发或转移性乳腺癌的一线治疗：一项2期随机研究。
Breast. 2015 Jun;24(3):182-90. doi: 10.1016/j.breast.2014.11.003. Epub 2015 Mar 5.
Zotero 插件